MiMedx GroupMDXG
MDXG
About: MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are primarily targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, it sells allografts for ophthalmic surgery and dental applications through licenses to third parties.
Employees: 837
0
Funds holding %
of 7,296 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
33% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 21
1% more funds holding
Funds holding: 212 [Q4 2024] → 215 (+3) [Q1 2025]
1% more repeat investments, than reductions
Existing positions increased: 70 | Existing positions reduced: 69
0.16% more ownership
Funds ownership: 68.75% [Q4 2024] → 68.91% (+0.16%) [Q1 2025]
0% more funds holding in top 10
Funds holding in top 10: 4 [Q4 2024] → 4 (+0) [Q1 2025]
3% less call options, than puts
Call options by funds: $1.01M | Put options by funds: $1.04M
21% less capital invested
Capital invested by funds: $972M [Q4 2024] → $772M (-$200M) [Q1 2025]
Research analyst outlook
We haven’t received any recent analyst ratings for MDXG.
Financial journalist opinion
Neutral
GlobeNewsWire
2 weeks ago
MIMEDX to Participate in Upcoming Investor Conferences
MARIETTA, Ga., May 27, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that members of its senior management will participate in the following investor conferences: Craig-Hallum 22 nd Annual Institutional Investor Conference | Minneapolis, MN 1:1 sessions: Wednesday, May 28, 2025 Goldman Sachs 46 th Annual Global Healthcare Conference | Miami, FL 1:1 sessions: Wednesday, June 11, 2025 Northland Capital Growth Conference | Virtual 1:1 sessions: Wednesday, June 25, 2025 Investors interested in meeting with senior management at these events may contact their respective Craig-Hallum, Goldman Sachs or Northland representative.
Neutral
GlobeNewsWire
1 month ago
MIMEDX to Present at the BofA Securities 2025 Healthcare Conference
MARIETTA, Ga., May 06, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that members of its senior management will participate in the BofA Securities 2025 Healthcare Conference in Las Vegas, NV.
Neutral
GlobeNewsWire
1 month ago
MIMEDX Announces Publication of Health Economics Data in Mohs Micrographic Surgery (MMS)
Propensity Score-Matched, Comparative Cost-Effectiveness Analysis of the Company's EPIFIX® Placental Allograft Product Propensity Score-Matched, Comparative Cost-Effectiveness Analysis of the Company's EPIFIX® Placental Allograft Product
Neutral
Seeking Alpha
1 month ago
MiMedx Group, Inc. (MDXG) Q1 2025 Earnings Call Transcript
MiMedx Group, Inc. (NASDAQ:MDXG ) Q1 2025 Earnings Conference Call April 30, 2025 4:30 PM ET Company Participants Matthew Notarianni - Head, IR Joseph Capper - CEO & Director Doug Rice - CFO Conference Call Participants Carl Byrnes - Northland Capital Markets Chase Knickerbocker - Craig-Hallum Capital Group Ross Osborn - Cantor Fitzgerald Anthony Petrone - Mizuho Group Operator Good afternoon, and thank you for standing by. Welcome to the MIMEDX First Quarter 2025 Operating and Financial Results Conference Call.
Positive
Zacks Investment Research
1 month ago
MiMedx (MDXG) Q1 Earnings Match Estimates
MiMedx (MDXG) came out with quarterly earnings of $0.06 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.07 per share a year ago.
Neutral
GlobeNewsWire
1 month ago
MIMEDX Announces First Quarter 2025 Operating and Financial Results
Net Sales of $88 million Grew 4% Year-Over-Year for the First Quarter First Quarter GAAP Net Income and Earnings Per Share were $7 Million and $0.05, Respectively First Quarter Adjusted EBITDA was $17 Million, or 20% of Net Sales Reaffirms Expected 2025 Net Sales Growth Expectations Management to Host Conference Call Today, April 30, 2025 , at 4:30 PM ET MARIETTA, Ga., April 30, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), today announced operating and financial results for the first quarter 2025.
Neutral
GlobeNewsWire
2 months ago
MIMEDX to Feature Growing Body of Clinical and Scientific Evidence at Upcoming Wound & Surgical-Focused Industry Conferences
MARIETTA, Ga., April 10, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that it will participate in the following industry conferences this quarter to feature the latest scientific and clinical data supporting the use of its portfolio of Advanced Wound Care and Surgical Solutions.
Neutral
GlobeNewsWire
3 months ago
MIMEDX to Present at TD Cowen 45th Annual Health Care Conference
MARIETTA, Ga., Feb. 27, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that senior management will participate in the TD Cowen 45th Annual Health Care Conference.
Neutral
Seeking Alpha
3 months ago
MiMedx Group, Inc. (MDXG) Q4 2024 Earnings Call Transcript
MiMedx Group, Inc. (NASDAQ:MDXG ) Q4 2024 Earnings Conference Call February 26, 2024 4:30 AM ET Company Participants Matt Notarianni - Head, Investor Relations Joseph Capper - Chief Executive Officer Doug Rice - Chief Financial Officer Conference Call Participants Chase Knickerbocker - Craig-Hallum Group Ross Osborn - Cantor Fitzgerald Bradley Bowers - Mizuho Securities Brooks O'Neil - Lake Street Capital Markets Carl Byrnes - Northland Capital Markets Operator Good afternoon, and thank you for standing by. Welcome to the MiMedx Fourth Quarter and Full Year 2024 Operating Financial Results Conference Call.
Positive
Zacks Investment Research
3 months ago
MiMedx (MDXG) Q4 Earnings Meet Estimates
MiMedx (MDXG) came out with quarterly earnings of $0.07 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.04 per share a year ago.
Charts implemented using Lightweight Charts™